These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34877907)

  • 1. Determining similarities of COVID-19 - lung cancer drugs and affinity binding mode analysis by graph neural network-based GEFA method.
    Budak C; Mençik V; Gider V
    J Biomol Struct Dyn; 2023 Feb; 41(2):659-671. PubMed ID: 34877907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of oral therapeutics using an AI platform against the virus responsible for COVID-19, SARS-CoV-2.
    Bess A; Berglind F; Mukhopadhyay S; Brylinski M; Alvin C; Fattah F; Wasan KM
    Front Pharmacol; 2023; 14():1297924. PubMed ID: 38186640
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug repositioning against COVID-19: a first line treatment.
    Bibi N; Farid A; Gul S; Ali J; Amin F; Kalathiya U; Hupp T
    J Biomol Struct Dyn; 2022; 40(23):12812-12826. PubMed ID: 34519259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.
    Kandeel M; Abdelrahman AHM; Oh-Hashi K; Ibrahim A; Venugopala KN; Morsy MA; Ibrahim MAA
    J Biomol Struct Dyn; 2021 Sep; 39(14):5129-5136. PubMed ID: 32597315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19.
    Apaydın ÇB; Çınar G; Cihan-Üstündağ G
    Curr Drug Targets; 2021; 22(17):1986-2005. PubMed ID: 33588727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In a search for potential drug candidates for combating COVID-19: computational study revealed salvianolic acid B as a potential therapeutic targeting 3CLpro and spike proteins.
    Elmaaty AA; Darwish KM; Khattab M; Elhady SS; Salah M; Hamed MIA; Al-Karmalawy AA; Saleh MM
    J Biomol Struct Dyn; 2022; 40(19):8866-8893. PubMed ID: 33928870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
    Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M
    In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated docking and enhanced sampling-based selection of repurposing drugs for SARS-CoV-2 by targeting host dependent factors.
    Kumawat A; Namsani S; Pramanik D; Roy S; Singh JK
    J Biomol Struct Dyn; 2022; 40(20):9897-9908. PubMed ID: 34155961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2.
    Anwaar MU; Adnan F; Abro A; Khan RA; Rehman AU; Osama M; Rainville C; Kumar S; Sterner DE; Javed S; Jamal SB; Baig A; Shabbir MR; Ahsan W; Butt TR; Assir MZ
    Comput Biol Med; 2022 Feb; 141():105049. PubMed ID: 34823857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Insights and Molecular Docking Studies of the Drugs under Clinical Trial as RdRp Inhibitors in COVID-19 Treatment.
    Pauly I; Kumar Singh A; Kumar A; Singh Y; Thareja S; Kamal MA; Verma A; Kumar P
    Curr Pharm Des; 2022; 28(46):3677-3705. PubMed ID: 36345244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological Strategies for COVID-19 - A Review of the Most Promising Repurposed Antiviral Drugs.
    Chopra D; Boparai JK; Bhandari B; Srivastava A; Gupta R
    Infect Disord Drug Targets; 2021; 21(7):e160921189260. PubMed ID: 33342420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. State-of-the-art Tools to Elucidate the Therapeutic Potential of TAT-peptide (TP) Conjugated Repurposing Drug Against SARS-CoV-2 Spike Glycoproteins.
    Ansari MA; Alomary MN; Jamal QMS; Almoshari Y; Salawi A; Almahmoud SA; Khan J
    Curr Pharm Des; 2022; 28(46):3706-3719. PubMed ID: 36278465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment.
    Taibe NS; Kord MA; Badawy MA; Shytaj IL; Elhefnawi MM
    Ther Adv Respir Dis; 2022; 16():17534666221132736. PubMed ID: 36282077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19.
    Talluri S
    Comb Chem High Throughput Screen; 2021; 24(5):716-728. PubMed ID: 32798373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phylogenic analysis of coronavirus genome and molecular studies on potential anti-COVID-19 agents from selected FDA-approved drugs.
    Ishola AA; Adewole KE; Tijjani H; Abdulai SI; Asogwa NT
    J Biomol Struct Dyn; 2022 Oct; 40(17):7726-7743. PubMed ID: 33749538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials.
    Paul SS; Biswas G
    Mini Rev Med Chem; 2021; 21(9):1123-1143. PubMed ID: 33355053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.